Cargando…

Prevalence and Severity of Potential Drug–Drug Interactions in Patients with Multiple Sclerosis with and without Polypharmacy

Polypharmacy (PP) is a common problem in modern medicine, especially known to affect patients with chronic diseases such as multiple sclerosis (MS). With an increasing number of drugs taken, the risk of potential drug–drug interactions (pDDIs) is rising. This study aims to assess the prevalence and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bachmann, Paula, Frahm, Niklas, Debus, Jane Louisa, Mashhadiakbar, Pegah, Langhorst, Silvan Elias, Streckenbach, Barbara, Baldt, Julia, Heidler, Felicita, Hecker, Michael, Zettl, Uwe Klaus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949310/ https://www.ncbi.nlm.nih.gov/pubmed/35335968 http://dx.doi.org/10.3390/pharmaceutics14030592

Ejemplares similares

Associated factors of potential drug-drug interactions and drug–food interactions in patients with multiple sclerosis
por: Debus, Jane Louisa, et al.
Publicado: (2022)

Screening for severe drug-drug interactions in patients with multiple sclerosis: A comparison of three drug interaction databases
por: Hecker, Michael, et al.
Publicado: (2022)

Therapy of women with multiple sclerosis: an analysis of the use of drugs that may have adverse effects on the unborn child in the event of (unplanned) pregnancy
por: Haker, Marie-Celine, et al.
Publicado: (2023)

Depression and Anxiety in Association with Polypharmacy in Patients with Multiple Sclerosis
por: Baldt, Julia, et al.
Publicado: (2023)

Vaccination Coverage against Tetanus, Diphtheria, Pertussis and Poliomyelitis and Validity of Self-Reported Vaccination Status in Patients with Multiple Sclerosis
por: Langhorst, Silvan Elias, et al.
Publicado: (2022)

Vaccination willingness in association with personality traits in patients with multiple sclerosis in the course of SARS-CoV-2 pandemic
por: Heidler, Felicita, et al.
Publicado: (2022)

The risk of polypharmacy, comorbidities and drug–drug interactions in women of childbearing age with multiple sclerosis
por: Frahm, Niklas, et al.
Publicado: (2020)

Polypharmacy in patients with multiple sclerosis: a gender-specific analysis
por: Frahm, Niklas, et al.
Publicado: (2019)

Polypharmacy in outpatients with relapsing-remitting multiple sclerosis: A single-center study
por: Frahm, Niklas, et al.
Publicado: (2019)

Multi-drug use among patients with multiple sclerosis: A cross-sectional study of associations to clinicodemographic factors
por: Frahm, Niklas, et al.
Publicado: (2019)

Systematic Review of Studies on Telomere Length in Patients with Multiple Sclerosis
por: Bühring, Jan, et al.
Publicado: (2021)

POLYPHARMACY VERSUS DRUG COMBINATIONS
por: Agarwal, A.K.
Publicado: (1991)

Analysis of microRNA and Gene Expression Profiles in Multiple Sclerosis: Integrating Interaction Data to Uncover Regulatory Mechanisms
por: Freiesleben, Sherry, et al.
Publicado: (2016)

Genetic, Environmental and Lifestyle Determinants of Accelerated Telomere Attrition as Contributors to Risk and Severity of Multiple Sclerosis
por: Hecker, Michael, et al.
Publicado: (2021)

Aggressive multiple sclerosis: a matter of measurement and timing
por: Ellenberger, David, et al.
Publicado: (2020)

Drug-drug interactions in polypharmacy patients: The impact of renal impairment
por: Papotti, Bianca, et al.
Publicado: (2021)

Targeting continuity of care and polypharmacy to reduce drug–drug interaction
por: Weng, Yi-An, et al.
Publicado: (2020)

Leukocyte Telomere Length in Patients with Multiple Sclerosis and Its Association with Clinical Phenotypes
por: Hecker, Michael, et al.
Publicado: (2021)

Adverse drug reactions and polypharmacy in cardiac patients
por: Mugoša, Snežana, et al.
Publicado: (2012)

Polypharmacy - is there a cure for drug therapy problems?
por: Orehovački, Helena, et al.
Publicado: (2023)

Treatment patterns in pediatric patients with multiple sclerosis in Germany—a nationwide claim-based analysis
por: Frahm, Niklas, et al.
Publicado: (2021)

Polypharmacy and potential drug–drug interactions in emergency department patients in the Caribbean
por: Dookeeram, Darren, et al.
Publicado: (2017)

Genetic risk variants for multiple sclerosis are linked to differences in alternative pre-mRNA splicing
por: Putscher, Elena, et al.
Publicado: (2022)

Polypharmacy, Drug–Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV
por: Courlet, Perrine, et al.
Publicado: (2019)

Drug-drug interactions and adverse drug reactions in polypharmacy among older adults: an integrative review
por: Rodrigues, Maria Cristina Soares, et al.
Publicado: (2016)

Polypharmacy and potential drug–drug interactions among Greenland’s care home residents
por: Albertsen, Nadja, et al.
Publicado: (2022)

Prescription Advice Based on Data of Drug-Drug-Gene Interaction of Patients with Polypharmacy
por: Salamone, Sandro, et al.
Publicado: (2022)

Evaluation of potential drug-drug interactions and polypharmacy in hospitalized COVID-19 patients
por: Kilit, Türkan Paşalı, et al.
Publicado: (2022)

Adverse drug reactions in the era of multi-morbidity and polypharmacy
por: Birriel, T. Javier, et al.
Publicado: (2015)

Prognostic impact of polypharmacy by drug essentiality in patients on hemodialysis
por: Kitamura, Mineaki, et al.
Publicado: (2021)

Glatiramer acetate treatment effects on gene expression in monocytes of multiple sclerosis patients
por: Thamilarasan, Madhan, et al.
Publicado: (2013)

Reduced Fragmentation of IGFBP-2 and IGFBP-3 as a Potential Mechanism for Decreased Ratio of IGF-II to IGFBPs in Cerebrospinal Fluid in Response to Repeated Intrathecal Administration of Triamcinolone Acetonide in Patients With Multiple Sclerosis
por: Hoeflich, Andreas, et al.
Publicado: (2021)

Frequency and Predictors of Relapses following SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis: Interim Results from a Longitudinal Observational Study
por: Frahm, Niklas, et al.
Publicado: (2023)

Rituximab versus mitoxantrone: comparing effectiveness and safety in advanced relapsing multiple sclerosis
por: Zrzavy, Tobias, et al.
Publicado: (2021)

Antiepileptic and Antidepressive Polypharmacy in Patients with Multiple Sclerosis
por: Beiske, Georg Anton Giæver, et al.
Publicado: (2015)

Microarray data of transcriptome shifts in blood cell subsets during S1P receptor modulator therapy
por: Koczan, Dirk, et al.
Publicado: (2018)

MicroRNA Expression Changes during Interferon-Beta Treatment in the Peripheral Blood of Multiple Sclerosis Patients
por: Hecker, Michael, et al.
Publicado: (2013)

The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010
por: Guthrie, Bruce, et al.
Publicado: (2015)

Polypharmacy, Potentially Inappropriate Medications, and Drug-to-Drug Interactions in Patients with Chronic Myeloproliferative Neoplasms
por: Krečak, Ivan, et al.
Publicado: (2023)

Polypharmacy, potentially inappropriate medications, and drug-drug interactions in older COVID-19 inpatients
por: Chen, Zhaoyan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9832la5f7dgto5etpa1mekor28